Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients
Status:
Completed
Trial end date:
2007-11-26
Target enrollment:
Participant gender:
Summary
Sufficient subjects with a confirmed diagnosis of MS (EDSS score of 6.5 or below), will be
recruited to ensure that 30 subjects (approx. equal numbers of each gender) complete the
study. Subjects will undergo a screening visit, then four study days, each separated by a
washout period of at least 7 days, when the different firategrast batches of drug substance
will be administered, and a follow-up visit.